Efficacy of intra-articular of high molecular weight hyaluronic acid injections in in osteoarthritis of the knee and hip
https://doi.org/10.51793/OS.2021.24.7.008
Abstract
The presence of pain syndrome and an increase in functional insufficiency of the joints are the most frequent reasons for patients seeking medical help. Currently, given the growing prevalence of osteoarthritis, a more active multimodal approach to patient management is needed, taking into account their individual characteristics and needs. The main goals of osteoarthritis therapy are: pain relief; maintaining or improving joint function; preventing the build-up of functional impairment, improving health-related quality of life, and reducing/preventing structural progression of the disease. The article presents data on one of the effective and safe methods of treating osteoarthritis of the knee and hip joints – intra-articular administration of hyaluronic acid, which provides a significant reduction in pain, improvement of joint function; helps to reduce the need for NSAIDs and slow the progression of the disease. The obtained research results indicate a good and long-term symptomatic effect of the drug, a high safety profile and the possibility of its use in wide clinical practice.
About the Authors
L. I. Alekseeva
V. A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Россия
Россия
Moscow
N. G. Kashevarova
V. A. Nasonova Research Institute of Rheumatology
Россия
Россия
Moscow
References
1. Alekseeva L. I., Taskina E. A., Kashevarova N. G. Osteoartrit: epidemiologiya, klassifikatsiya, faktory riska I proressirovaniya, klinika, diagnostika, lechenie [Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment] // Modern Rheumatology Journal. 2019; 13 (2): 9-21. (In Russ.) Available from: https://doi.org/10.14412/1996-7012-2019-2-9-21.
2. Cross M., Smith E., Hoy D., et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study // Ann Rheum Dis. 2014; 73 (7): 1323-1330. DOI: 10.1136/annrheumdis-2013-204763.
3. Nüesch E., Dieppe P., Reichenbach S. et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study // BMJ. 2011; 342: d1165. DOI: 10.1136/bmj.d1165.
4. Bannuru R. R., Osani M. C., Vaysbrot E. E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis // Osteoarthritis Cartilage. 2019; 27 (11): 1578-1589. DOI: 10.1016/j.joca.2019.06.011.
5. Bruyère O., Honvo G., Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum // Semin Arthritis Rheum. 2019; pii: S0049–0172 (19): 30043–30045. DOI: 10.1016/j.semarthrit.2019.04.008.
6. Kolasinski L. Sharon, Neogi T., Hochberg C. Marc. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee // Arthritis Care & Research. 2020: 1-14. DOI: 10.1002/acr.24131.
7. Kloppenburg M., Kroon Féline P. B., Blanco J. Francisco et al. // Ann Rheum Dis. 2019; 78: 16-24. DOI: 10.1136/annrheumdis-2018-213826.
8. Ministry of Health of the Russian Federation. Osteoarthritis. Clinical recommendations. M., 2016.
9. Georgiev T., Angelov A. K. Modifiable risk factors in knee osteoarthritis: treatment implications // Rheumatol Int. 2019; 39 (7): 1145-1157. DOI: 10.1007/s00296-019-04290-z.
10. Meyer K., Palmer J. The polysaccharide of the vitreous humor // J. Biol. Chem. 1934; 107: 629-634.
11. Necas J., Bartosikova L., Brauner P., Kolar J. Hyaluronic acid (hyaluronan): A review // Vet. Med. 2008; 53: 397-411. DOI: 10.17221/1930-VETMED.
12. Kogan G., Šolté L., Stern R., Mendichi R. Hyaluronic acid: A biopolymer with versatile physico-chemical and biological properties. In: Pethrick R. A., Ballada A., Zaikov G. E., editors. Handbook of Polymer Research: Monomers, Oligomers, Polymers and Composites. Nova Science Publishers; Hauppauge, NY, USA: 2007. P. 393-439.
13. Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic Acid in the Third Millennium // Polymers (Basel). 2018; 10 (7).
14. De Oliveira J. D., Carvalho L. S., Gomes A. M., Queiroz L. R., Magalhães B. S., Parachin N. S. Genetic basis for hyper production of hyaluronic acid in natural and engineered microorganisms // Microb Cell Fact. 2016; 15 (1): 119.
15. Wang Y., Hu L., Huang H., Wang H., Zhang T., Chen J., Du G., Kang Z. Eliminating the capsule-like layer to promote glucose uptake for hyaluronan production by engineered Corynebacterium glutamicum // Nat Commun. 2020; 11 (1): 3120.
16. Boeriu C. G., Springer J., Kooy F. K., van den Broek L. A. M., Eggink G. Production methods for hyaluronan // Int. J. Carbohydr. Chem. 2013; 2013: 1-14. DOI: 10.1155/2013/624967.
17. Laurent T. C., Laurent U. B., Fraser J. R. The structure and function of hyaluronan: An overview // Immunol Cell Biol. 1996; 74 (2): A1-7.
18. Burmester G., Lanas A., Biasucci L., Hermann M., Lohmander S., Olivieri I., Scarpignato C., Smolen J., Hawkey C., Bajkowski A., Berenbaum F., Breedveld F., Dieleman P., Dougados M., MacDonald T., Mola E. M., Mets T., van den Noortgate N., Stoevelaar H. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel // Ann Rheum Dis. 2011; 70 (5): 818-822.
19. Bannuru R. R., Natov N. S., Obadan I. E., Price L. L., Schmid C. H., McAlindon T. E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis // Arthritis Rheum. 2009; 61: 1704-1711. DOI: 10.1002/art.24925.
20. Narayanan S., Suhail A., Harjeet S., Shahril Y., Masbah O. Efficacy of intra-articular injection of hyaluronic acid in the treatment of knee osteoarthritis // Malaysian Orthop J. 2009; 3 (1): 19-23. DOI: 10.5704/MOJ.0905.002.
21. Bannuru R. R., Schmid C. H., Kent D. M., Vaysbrot E. E., Wong J. B., McAlindon T. E. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis // Ann Intern Med. 2015; 162 (1): 46-54.
22. Richette P., Chevalier X., Ea H. K., Eymard F., Henrotin Y., Ornetti P., et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias // Rheum Musculoskelet Dis. 2015; 1: e000071.
23. Delbarre A., Amor B., Bardoulat I., Tetafort A., PelletierFleury N. Do intra-articular hyaluronic acid injections delay total knee replacement in patients with osteoarthritis A Cox model analysis // PLoS One. 2017; 12 (11): e0187227.
24. Cooper C., Rannou O. I. S., Richette P., Ere O. B., Al-daghri N., Altman R. O. Y. D., et al. Use of Intraarticular hyaluronic acid in the Management of Knee Osteoarthritis in clinical practice // Arthritis Ann Intern Med Care Res. 2017; 69 (9): 1287-1296. DOI: 10.1002/acr.23204.
25. Altman R., Lim S., Steen R. G., Dasa V. Hyaluronic acid injections are associated with delay of Total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database // PLoS One. 2015; 10 (12): e0145776. DOI: 10.1371/journal.pone.0145776.
26. Altman R., Fredericson M., Bhattacharyya S. K., Bisson B., Abbott T., Yadalam M. B. A. S., et al. Association between hyaluronic acid injections and time-to-Total knee replacement surgery // J Knee Surg. 2016; 29 (7): 564-570. DOI: 10.1055/s-0035-1568992.
27. Altman R. D., Manjoo A., Fierlinger A., Niazi F., Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review // BMC Musculoskelet Disord. 2015; 16: 321. DOI: 10.1186/s12891-015-0775-z.
28. Finelli I., Chiessi E., Galesso D., Renier D., Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study // Biorheology. 2011; 48 (5): 263-75.
29. Schieb F. Intraartikulärinjizierte-Hyaluronsäurebeiarthropathien // Arthritis Rheum. 2003; 6: 338-340.
30. Foti C., Cisari C., Carda S., Giordan N., Rocco A., Frizziero A., Della Bella G. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with osteoarthritis // Eur J Phys Rehabil Med. 2011; 47 (3): 407-415.
31. Priano F., Guelfi M. Efficacy of intra-articular hyaluronic acid (Hyalubrix ® ) in arthroscopy // Artroscopia. 2007; 8: 1-12.
32. Filardo G., Di Matteo B., Di Martino A., et al. Platelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Tria // Am J Sports Med. 2015; 43 (7): 1575-1582.
33. Migliore A., Martin L. S., Alimonti A., et al. Efficacy and safety of viscosupplementation by ultrasound-guided intraarticular injection in osteoarthritis of the hip // Osteoarthritis Cartilage. 2003; 11 (4): 305-306.
34. Migliore A., Tormenta S., Laganà B., et al. Safety of intra-articular hip injection of hyaluronic acid products by ultrasound guidance: an open study from ANTIAGE register // Eur Rev Med Pharmacol Sci. 2013; 17 (13): 1752-1759.
35. Migliore A., Bizzi E., Massafra U., et al. 18 months followup after intra-articular administration of Hyalubrix ® in 344 patients with symptomatic osteoarthritis of the hip // Osteoarthritisand Cartilage. 2008; 16 (S4): S118-S119.
36. Migliore A., Massafra U., Bizzi E., et al. Intra-articular injection of hyaluronic acid (MW 1,500-2,000 kDa; HyalOne) in symptomatic osteoarthritis of the hip: a prospective cohort study // Arch Orthop Trauma Surg. 2011; 131 (12): 1677-1685.
37. Migliore A., Massafra U., Bizzi E., et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip // Arthritis Res Ther. 2009; 11 (6): R183.
38. Migliore A., Bella A., Bisignani M., et al. Total hip replacement rate in a cohort of patients affected by symptomatic hip osteoarthritis following intra-articular sodium hyaluronate (MW 1,500-2,000 kDa) ORTOBRIX study // Clin Rheumatol. 2012; 31 (8): 1187-1196.
39. Migliore A., Massafra U., Frediani B., et al. HyalOne ® in the treatment of symptomatic hip OA – data from the ANTIAGE register: seven years of observation // Eur Rev Med Pharmacol Sci. 2017; 21 (7): 1635-1644.
Review
For citations:
Alekseeva L.I., Kashevarova N.G. Efficacy of intra-articular of high molecular weight hyaluronic acid injections in in osteoarthritis of the knee and hip. Lechaschi Vrach. 2021;(7):39-44. (In Russ.) https://doi.org/10.51793/OS.2021.24.7.008
Views:
331
JATS XML
Email this article 
